Characterization of gut microbiota in children with pulmonary tuberculosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the composition of gut microbiota in pediatric patients with pulmonary tuberculosis (PTB) compared with healthy controls. Researchers collected fecal samples upon admission and analyzed microbial DNA using 16SrDNA sequencing on the Illumina MiSeq platform. A follow-up assessment was also conducted one month after anti-tuberculosis treatment to track changes in the gut microbiota over the course of therapy.
Who was studied?
The study population consisted of pediatric patients diagnosed with pulmonary tuberculosis alongside healthy pediatric controls, using a case-controlled design. Fecal samples were gathered from both groups at admission, with PTB patients reassessed one month later following anti-tuberculosis treatment. The abstract does not specify exact sample sizes or additional demographic details beyond the pediatric PTB and healthy control groups.
What were the most important findings?
Children with pulmonary tuberculosis showed decreased microbial diversity in their gut microbiota compared with healthy controls. PTB patients had increased levels of the pro-inflammatory bacterium Prevotella and the opportunistic pathogen Enterococcus. At the same time, beneficial bacteria including Ruminococcaceae, Bifidobacteriaceae, and Faecalibacterium prausnitzii were reduced. One month after anti-tuberculosis therapy, the richness of the gut microbiota was further depleted.
What are the greatest implications of this study?
These findings suggest that pulmonary tuberculosis in children is associated with a disrupted gut microbiota, marked by loss of diversity and depletion of beneficial, anti-inflammatory commensals such as Faecalibacterium prausnitzii, alongside expansion of pro-inflammatory and opportunistic organisms. The further depletion of microbial richness after anti-tuberculosis treatment raises the possibility that therapy itself compounds gut microbial disruption in these children. This points to the gut microbiota as a potentially important, underexplored factor in the physiological response to pulmonary tuberculosis and its treatment in pediatric patients.